Skip to main content

Table 2 Associations between number of AR CAG repeats and ESR2 CA repeats and overall as well as disease-specific survival

From: Repeat polymorphisms in ESR2 and ARand colorectal cancer risk and prognosis: results from a German population-based case-control study

  Overall Women Men pheterogeneityc
Genotype OS HR (95%CI)b DSS HR (95%CI)b OS HR (95% CI)b DSS HR (95%CI)b OS HR (95%CI)b DSS HR (95% CI)b OS DSS
AR CAG( n)         
<20 average repeats 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)   
≥20 to <22 average repeats 1.09 (0.78 - 1.53) 1.14 (0.77 - 1.69) 0.90 (0.50 - 1.62) 1.21 (0.59 - 2.47) 1.28 (0.84 - 1.97) 1.20 (0.73 - 2.00)   
≥22 to <23.5 average repeats 1.11 (0.76 - 1.61) 1.26 (0.82 - 1.95) 0.90 (0.49 - 1.64) 1.17 (0.56 - 2.46) 1.12 (0.67 - 1.88) 1.34 (0.74 - 2.42)   
≥23.5 average repeats 1.03 (0.72 - 1.46) 1.04 (0.69 - 1.58) 0.75 (0.41 - 1.37) 0.93 (0.44 - 1.96) 1.22 (0.78 - 1.91) 1.24 (0.72 - 2.12) 0.83c 0.99c
average repeatsa 1.00 (0.96 - 1.05) 1.01 (0.95 - 1.06) 0.96 (0.88 - 1.04) 0.98 (0.89 - 1.08) 1.02 (0.96 - 1.07) 1.03 (0.96 - 1.10) 0.45d 0.93d
  p trend =0.97 p trend =0.84 p trend =0.31 p trend =0.67 p trend =0.56 p trend =0.46   
<22/<22 repeats 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)   
<22/≥22 repeats 0.95 (0.70 - 1.28) 0.95 (0.66 - 1.36) 0.96 (0.62 - 1.49) 0.97 (0.59 - 1.60) (no heterozygous) (no heterozygous)   
≥22/≥22 repeats 1.03 (0.80 - 1.33) 1.12 (0.84 - 1.51) 0.94 (0.58 - 1.53) 1.09 (0.63 - 1.89) 1.01 (0.74 - 1.37) 1.14 (0.78 - 1.65) 0.91d 0.60d
  p trend =0.80 p trend =0.45 p trend =0.82 p trend =0.73 p trend =0.95 p trend =0.50   
ESR2 CA( n)         
<22 average repeats 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)   
≥22 to <23.5average repeats 0.82 (0.59 - 1.15) 0.92 (0.61 - 1.39) 0.66 (0.38 - 1.15) 0.79 (0.42 - 1.47) 0.76 (0.51 - 1.14) 1.11 (0.63 - 1.97)   
≥23.5 to <24 average repeats 0.93 (0.64 - 1.35) 1.12 (0.73 - 1.73) 1.15 (0.67 - 1.98) 1.16 (0.61 - 2.20) 0.91 (0.54 - 1.53) 1.30 (0.69 - 2.44)   
≥24 average repeats 0.76 (0.56 - 1.02) 0.91 (0.64 - 1.29) 0.73 (0.47 - 1.15) 0.80 (0.50 - 1.38) 0.83 (0.50 - 1.38) 1.00 (0.60 - 1.65) 0.56c 0.96c
average repeatsa 0.95 (0.89 - 1.02) 0.99 (0.91 - 1.07) 0.95 (0.86 - 1.06) 0.96 (0.86 - 1.08) 0.95 (0.86 - 1.03) 1.00 (0.89 - 1.12) 0.85d 0.81d
  p trend =0.14 p trend =0.72 p trend =0.35 p trend =0.54 p trend =0.22 p trend =0.99   
<24/<24 repeats 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)   
<24/≥24 repeats 0.79 (0.59 - 1.07) 0.88 (0.62 - 1.26) 0.74 (0.46 - 1.20) 0.89 (0.51 - 1.55) 0.88 (0.60 - 1.29) 0.99 (0.62- 1.58)   
≥24/≥24 repeats 0.73 (0.53 - 1.00) 0.82 (0.57 - 1.19) 0.67 (0.40 - 1.12) 0.78 (0.43 - 1.40) 0.76 (0.51 - 1.15) 0.89 (0.54 - 1.46) 0.81d 0.84d
  p trend =0.06 p trend =0.31 p trend =0.15 p trend =0.39 p trend =0.19 p trend =0.62   
  1. aAs continuous variable, bStratified for grade of differentiation (well/moderate, poor/undifferentiated) and adjusted for diagnosis of other cancer after colorectal cancer diagnosis (yes/no), colorectal cancer detected by screening (yes/no), treatment with adjuvant chemotherapy (yes/no), tumour extent (T1, T2, T3, T4), nodal status (N0, N1, N2), distant metastasis (M0, M1), BMI (kg/m2, continuous), age at diagnosis and year of diagnosis, cP-value for heterogeneity by gender with genotype in categories (3df), dP-value for heterogeneity by gender with genotype as continuous variable (1df), OS: overall survival, DSS: disease-specific survival, HR: hazard ratio, CI: confidence interval.